Insider trading

Period: 120 months Stock: HRTX Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

37 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

37 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

37 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

37 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
37 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
37 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

37 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
3 May 2022
MANHARD KIMBERLY EVP, Drug Development
Sold, plan not stated
$7.15K 1,504 at 4.76
12.2%
21 Dec 2021
Christian Waage Director
Sold, plan not stated
$2.92K 300 at 9.73
8.6%
21 Dec 2021
Johnson Craig A Director
Sold, plan not stated
$2.43K 250 at 9.73
8.1%
21 Sep 2021
Christian Waage Director
Sold, plan not stated
$3.69K 300 at 12.31
7.9%
21 Sep 2021
Johnson Craig A Director
Sold, plan not stated
$3.07K 250 at 12.30
7.5%
21 Jun 2021
Christian Waage Director
Sold, plan not stated
$4.56K 300 at 15.20
7.3%
21 Jun 2021
Johnson Craig A Director
Sold, plan not stated
$3.80K 250 at 15.20
7.0%
3 May 2021
MANHARD KIMBERLY EVP, Drug Development
Sold, plan not stated
$27.01K 1,529 at 17.66
48.3%
15 Apr 2021
Christian Waage Director
Sold, plan not stated
$5.25K 300 at 17.51
6.8%
6 Apr 2021
Johnson Craig A Director
Sold, plan not stated
$4.31K 250 at 17.22
6.5%
14 Jan 2021
Szekeres David Leslie EVP, Chief Operating Officer
Sold, plan not stated
$14.96K 827 at 18.09
100%
Sold half or more
8 Jan 2021
Szekeres David Leslie EVP, Chief Operating Officer
Sold, plan not stated
$70.22K 3,571 at 19.66
100%
Sold half or more
22 Dec 2020
MANHARD KIMBERLY EVP, Drug Development
Sold, plan not stated
$200.00K 10,000 at 20.00
100%
Sold half or more
1 May 2020
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$16.18K 1,158 at 13.97
100%
Sold half or more
29 Nov 2019
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$624.00K 24,000 at 26.00
100%
Sold half or more
4 Oct 2019
TANG KEVIN Director · indirect
Bought
$5.00M 285,714 at 17.50
5.2%
First buy on file
3 Oct 2019
POYHONEN JOHN EVP, Chief Commercial Officer
Bought
$90.00K 5,143 at 17.50
39.6%
First buy on file
3 Oct 2019
Quart Barry D Chief Executive Officer
Bought
$79.99K 4,571 at 17.50
5.1%
First buy on file
22 May 2019
POYHONEN JOHN Director
Bought
$52.65K 3,000 at 17.55
30.0%
First buy on file
15 May 2019
Christian Waage Director
Bought
$25.26K 1,400 at 18.04
opened
First buy on file
1 May 2019
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$20.92K 1,109 at 18.86
100%
Sold half or more
2 Nov 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$15.12K 494 at 30.62
100%
Sold half or more
1 Oct 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$192.43K 6,000 at 32.07
100%
Sold half or more
12 Sep 2018
TANG KEVIN Director · indirect
Sold, plan not stated
$96.35M 2,695,000 at 35.75
31.6%
2 Jul 2018
Rosen Robert President
Sold, plan not stated 2×
$3.64M 95,531 at 38.15
97.3%
Sold half or more
2 Jul 2018
Hoffman Robert E. CFO & SVP, Finance
Sold, plan not stated 2×
$1.15M 30,000 at 38.17
95.9%
Sold half or more
2 Jul 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated 2×
$225.18K 6,000 at 37.53
100%
Sold half or more
29 Jun 2018
Rosen Robert President
Sold, plan not stated 3×
$5.13M 129,469 at 39.59
98.0%
Sold half or more
21 Jun 2018
Quart Barry D Chief Executive Officer
Sold, plan not stated
$1.95M 50,000 at 39.05
41.8%
29 Mar 2018
TANG KEVIN Director · indirect
Bought
$5.00M 192,308 at 26.00
2.3%
First buy on file
19 Mar 2018
Quart Barry D Chief Executive Officer
Sold, plan not stated
$2.98M 100,000 at 29.75
59.5%
Sold half or more
19 Mar 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$540.00K 18,000 at 30.00
100%
Sold half or more
14 Mar 2018
Quart Barry D Chief Executive Officer
Sold, plan not stated
$2.48M 100,000 at 24.75
59.5%
Sold half or more
10 Jan 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$151.68K 7,584 at 20.00
100%
Sold half or more
24 Apr 2017
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$330.26K 21,542 at 15.33
100%
Sold half or more
19 Jan 2017
TANG KEVIN Director · indirect
Bought
$30.00M 2,459,016 at 12.20
41.9%
First buy on file
19 Jan 2017
POYHONEN JOHN Director
Bought
$122.00K 10,000 at 12.20
opened
First buy on file
Showing 1–37 of 37.